Trimedyne Inc. Reports FDA OK on Laser Trials
- Share via
Trimedyne Inc. said it has received Food and Drug Administration approval for human trials of its Optilase Laser System and Coronary Laserprobe as an adjunct to bypass surgery in treatment of atherosclerosis of the heart.
The trials will involve patients with heavy calcium build-up in their arteries, said a spokeswoman for the Santa Ana-based company.
The laser-heated Trimedyne catheter alone may not be enough to remove the calcium deposits in such arteries, but could be effective when used a part of a conventional bypass operation, the spokeswoman said.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
